Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
Surg Endosc ; 32(9): 3936-3942, 2018 09.
Article in English | MEDLINE | ID: mdl-29492709

ABSTRACT

BACKGROUND: Endoscopic sleeve gastroplasty is a safe and feasible treatment for obesity. This study is focused on our technique modification which suggests a different suturing pattern in order to distribute suture tension more evenly. METHODS: A retrospective study of 148 patients (121 women) who underwent this procedure and were monitored for 12 months was conducted. The average age was 41.53 ± 10 years. The average BMI was 35.11 ± 5.5 kg/m2 with the average initial weight being 98.7 ± 17 kg. A subgroup of the first 72 patients (60 women) were monitored for 18 months. A new running "Z" stitch pattern was used to provide gastric cavity reduction by means of 4 parallel suture rows. The stitch pattern was intended to provide a homogenous distribution of the disruptive force on the suture among all stitch points. RESULTS: %TWL was 17.53 ± 7.57 in 12 months and 18.5 ± 9% in 18 months indicating durability of the procedure. Patients with a BMI < 35 benefited most from an endoscopic gastroplasty. Leptin did not predict a response to endoscopic gastroplasty and decreased in all patients. In just one case there was a mild bleeding (0.67%) at the insertion point of the helix, which was resolved by sclerotherapy. CONCLUSIONS: Endoscopic gastroplasty offers a real choice for obese patients. This single-center experience with a modified suturing pattern provides a successful technique for weight loss.


Subject(s)
Endoscopy/methods , Gastroplasty/methods , Obesity/surgery , Suture Techniques , Adult , Body Mass Index , Female , Humans , Leptin/blood , Male , Retrospective Studies , Weight Loss
2.
Eur J Nutr ; 51(3): 365-74, 2012 Apr.
Article in English | MEDLINE | ID: mdl-21688122

ABSTRACT

PURPOSE: The aim of this study was to better characterise the biological effects of Lactobacillus salivarius ssp. salivarius CECT5713, a probiotic with immunomodulatory properties. METHODS: Live or dead probiotic was assayed in the TNBS model of rat colitis to determine whether viability was a requisite to exert the beneficial effects. In vitro studies were also performed in Caco-2 cells to evaluate its effects on epithelial cell recovery and IL-8 production. Finally, the probiotic was assayed in the LPS model of septic shock in mice to establish its effects when there is an altered systemic immune response. RESULTS: The viability of the probiotic was required for its anti-inflammatory activity. The probiotic inhibited IL-8 production in stimulated Caco-2 cells and facilitated the recovery of damaged intestinal epithelium. In LPS-treated mice, the probiotic inhibited the production of TNFα in plasma and lungs and increased the hepatic glutathione content. These effects were associated with an improvement in the altered production of the T-cell cytokines in splenocytes, by reducing IL-2 and IL-5 and by increasing IL-10. Finally, it reduced the increased plasma IgG production in LPS-treated mice. CONCLUSION: The anti-inflammatory effects of viable L. salivarius ssp. salivarius CECT5713 are not restricted to the gastrointestinal tract.


Subject(s)
Colitis/therapy , Immunologic Factors/administration & dosage , Intestine, Large/microbiology , Lactobacillus/metabolism , Probiotics/administration & dosage , Animals , Anti-Inflammatory Agents/administration & dosage , Caco-2 Cells , Female , Glutathione/analysis , Humans , Immunoglobulin G/metabolism , Interleukin-10/metabolism , Interleukin-5/metabolism , Interleukin-8/metabolism , Intestinal Mucosa/metabolism , Lactobacillus/growth & development , Lipopolysaccharides/metabolism , Liver/metabolism , Male , Mice , Mice, Inbred BALB C , Rats , Rats, Wistar , Shock, Septic/pathology , Shock, Septic/prevention & control , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Tumor Necrosis Factor-alpha/blood
3.
Pharmacol Res ; 63(4): 308-19, 2011 Apr.
Article in English | MEDLINE | ID: mdl-21193045

ABSTRACT

Some antibiotics, including minocycline, have recently been reported to display immunomodulatory properties in addition to their antimicrobial activity. The use of a compound with both immunomodulatory and antibacterial properties could be very interesting in the treatment of inflammatory bowel disease (IBD), so the aim of our study was to evaluate the anti-inflammatory effect of minocycline in several experimental models of IBD. Firstly, the immunomodulatory activity of the antibiotic was tested in vitro using Caco-2 intestinal epithelial cells and RAW 264.7 macrophages; minocycline was able to inhibit IL-8 and nitrite production, respectively. In vivo studies were performed in trinitrobenzenesulfonic acid (TNBS)-induced rat colitis and dextran sodium sulfate (DSS)-induced mouse colitis. The results revealed that minocycline exerted an intestinal anti-inflammatory effect when administered as a curative treatment in the TNBS model, modulating both immune and microbiological parameters, being confirmed in the DSS model; whereas none of the other antibiotics tested (tetracycline and metronidazole) showed anti-inflammatory effect. However, minocycline administration before the colitis induction was not able to prevent the development of the intestinal inflammation, thus showing that only its antimicrobial activity is not enough for the anti-inflammatory effect. In conclusion, minocycline displays an anti-inflammatory effect on different models of rodent colitis which could be attributed to the association of its antibacterial and immunomodulatory properties.


Subject(s)
Anti-Inflammatory Agents/therapeutic use , Colitis/drug therapy , Immunologic Factors/therapeutic use , Minocycline/therapeutic use , Animals , Anti-Inflammatory Agents/pharmacology , Caco-2 Cells , Cell Line , Colitis/chemically induced , Colitis/pathology , Dextran Sulfate , Female , Humans , Immunologic Factors/pharmacology , Inflammatory Bowel Diseases/drug therapy , Macrophages/drug effects , Mice , Mice, Inbred C57BL , Minocycline/pharmacology , Rats , Rats, Wistar , Trinitrobenzenesulfonic Acid
4.
Clin Nutr ; 29(6): 832-9, 2010 Dec.
Article in English | MEDLINE | ID: mdl-20605664

ABSTRACT

Different types of dietary fiber can be distinguished considering their rate of fermentability, thus determining the location of the large intestine where they exert their beneficial effect. Their combination could be interesting to obtain health-promoting effects throughout the entire colon. The aim of the present study was to evaluate the synergistic effect of two dietary fibers with different fermentation patterns, fructooligosaccharides (FOS) (Beneo(®)-95) and resistant starch (Fibersol(®)-2), after their administration to healthy rats or in trinitrobenzenesulphonic acid-(TNBS) colitic rats, with an altered colonic immune response. In healthy rats, the administration of the combination of FOS and resistant starch induced changes in the intestinal microbiota, by increasing lactobacilli and bifidobacteria in caecum and colonic contents. Furthermore, its administration up-regulated the expression of the trefoil factor-3 and MUC-2 in comparison with untreated rats, thus improving the intestinal barrier function. The beneficial effects observed with this combination were confirmed in the TBNS model of rat colitis, since it was able to exert intestinal anti-inflammatory effect, associated with an increase of protective bacteria and up-regulation of epithelial defense mechanisms. In conclusion, the combination of two different dietary fibers may result in a synergistic prebiotic effect, and may confer greater health benefits to the host.


Subject(s)
Anti-Inflammatory Agents/pharmacology , Colitis/microbiology , Oligosaccharides/metabolism , Prebiotics/microbiology , Starch/metabolism , Animals , Colitis/metabolism , Colon/metabolism , Colon/microbiology , Dietary Fiber/pharmacology , Disease Models, Animal , Female , Fermentation , Lactobacillus/isolation & purification , Rats , Rats, Wistar , Up-Regulation
5.
J Agric Food Chem ; 58(10): 6476-84, 2010 May 26.
Article in English | MEDLINE | ID: mdl-20423151

ABSTRACT

In the present study we describe the preparation and chemical characterization of a caramel with a high (70%) content of difructose dianhydrides (DFAs) and glycosylated derivatives (DFAs). This product was obtained by thermal activation (90 degrees C) of highly concentrated (90% w/v) aqueous D-fructose solutions using the sulfonic acid ion-exchange resin Lewatit S2328 as caramelization catalyst. DFAs represent a unique family of cyclic fructans with prebiotic properties already present in low proportions (<15%) in commercial caramel. We report the antiinflammatory activity of the new DFA-enriched caramel in the trinitrobenzenesulfonic acid (TNBS) model of rat colitis, an experimental model that resembles human inflammatory bowel disease (IBD), and compare its effects with those obtained with a commercial sucrose caramel and with linear fructooligosaccharides (FOS). For this purpose, the effects on colon tissue damage, gut microbiota, short-chain fatty acid (SCFAs) production, and different inflammatory markers were evaluated. The administration of DFA-enriched caramel to colitic rats showed intestinal antiinflammatory effect, as evidenced macroscopically by a significant reduction in the extent of the colonic damage induced by TNBS. This effect was similar to that obtained with FOS in the same experimental settings, whereas commercial caramel was devoid of any significant antiinflammatory effect. The beneficial effect was associated with the inhibition of the colonic levels of the proinflammatory cytokines, tumor necrosis factor alpha (TNF alpha) and interleukin 1beta (IL-1beta), and the reduction in colonic myeloperoxidase (MPO) activity and inducible nitric oxide synthase (iNOS) expression. The DFA-enriched caramel also promoted a more favorable intestinal microbiota, increasing lactobacilli and bifidobacteria counts as well as inducing higher concentrations of SCFAs in the luminal colonic contents. These results reinforce the concept of DFAs and glycosyl-DFAs as dietary beneficial compounds with prebiotic properties and suggest that the novel DFA-enriched caramel here reported may be an interesting candidate to be explored for the dietary treatment of human IBD.


Subject(s)
Anti-Inflammatory Agents/administration & dosage , Candy , Colitis/drug therapy , Colon/microbiology , Disaccharides/administration & dosage , Animals , Candy/analysis , Colitis/chemically induced , Disaccharides/analysis , Disease Models, Animal , Female , Food Handling/methods , Food, Fortified , Glycosylation , Hot Temperature , Oligosaccharides/administration & dosage , Prebiotics , Rats , Rats, Wistar , Stereoisomerism , Sucrose/administration & dosage , Trinitrobenzenesulfonic Acid
6.
Br J Nutr ; 101(1): 51-8, 2009 Jan.
Article in English | MEDLINE | ID: mdl-18445307

ABSTRACT

The preventative effects of the probiotic Lactobacillus fermentum CECT5716 were evaluated in the lipopolysaccharide (LPS) model of septic shock in mice. The probiotic was administered suspended in drinking water at the final concentration of 108 colony-forming units/ml for 2 weeks before the induction of an endotoxic shock by an intraperitoneal injection of LPS (400 microg/200 microl per mouse). Blood and different organs were collected after 24 h to evaluate the severity of the endotoxic shock and the preventative effects of the probiotic. L. fermentum reduced TNF-alpha levels in blood, which promotes the major alterations observed during septic shock, as well as the infiltration of activated neutrophils into the lungs. Furthermore, free radical overproduction and oxidative stress were associated with a significant decrease in hepatic glutathione levels in septic mice, and with an excessive NO production attributed to the induction of the inducible isoform of NO synthase (iNOS). In fact, hepatic glutathione levels were significantly increased in the group of mice receiving the probiotic, and the increased iNOS expression both in the colon and lungs was down-regulated in those mice treated with L. fermentum. Finally, pre-treatment with L. fermentum may also exert its protective action modulating the expression of different cytokines in splenocyte-derived T cells such us IL-2, IL-5, IL-6 or IL-10. In conclusion, pre-treatment with L. fermentum may exert its protective action against LPS-induced organ damage in mice by a combination of several actions including its antioxidant properties and by reduction of the synthesis of the pro-inflammatory TNF-alpha and IL-6.


Subject(s)
Limosilactobacillus fermentum , Probiotics/therapeutic use , Shock, Septic/prevention & control , Animals , Cells, Cultured , Disease Models, Animal , Lipopolysaccharides , Lung/metabolism , Male , Mice , Mice, Inbred BALB C , Neutrophil Activation , Nitric Oxide Synthase Type II/metabolism , Spleen/metabolism , Tumor Necrosis Factor-alpha/biosynthesis , Tumor Necrosis Factor-alpha/blood
SELECTION OF CITATIONS
SEARCH DETAIL
...